REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

Go back to REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
Jennison Natural Resources Fund Class B (NASDAQ: RGNX) Delayed: 7.24 -0.16 (2.16%)
Previous Close $7.40    52 Week High $25.00 
Open $7.30    52 Week Low $7.07 
Day High $7.32    P/E N/A 
Day Low $7.17    EPS $0.00 
Volume 272,221